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Abstract 
The Role of Leukocyte Specific Protein 1 (LSP1) during HIV-1 Infection in Human T-Cells 
The Leukocyte Specific Protein 1 (LSP1) gene encodes a filament-actin 
binding protein that affects leukocyte motility via cytoskeleton remodeling. In 
dendritic cells, current data shows that LSP1 interacts with DC-SIGN and 
causes enhanced virus transfer to T-cells, while not typically infecting dendritic 
cells. However, while its association in several HIV-related signaling pathways 
has been shown, its primary role during HIV pathogenesis in T-cells is unknown. 
To explore the potential role of LSP1 during HIV-1 infection in T-cells, LSP1 
expression was altered in cell lines susceptible to cytopathic CXCR4-tropic HIV-
1 strains, which result in T-cell depletion characteristic of AIDS patients. Two 
different LSP1 mRNA binding sites were targeted for knockdown (KD) using an 
shRNA plasmid to transcriptionally silence LSP1 expression in MT4 cells, as well 
as a non-targeting shRNA control. The relative amount of free virus in the 
supernatant from infected cells was quantified by ELISA; LSP1-KD MT4 cells 
showed significant reduction in p24 levels by 3 days post-infection. This result 
was explored with an LTR-driven GHOST reporter to examine the relative levels 
of infectious vs. total virus produced. In this assay, LSP1-KD cells showed a 
significant reduction of infectious virion. An HIV-1 binding and entry assay 
showed significant reduction in binding in LSP1-KD cells, while the entry assay 
showed no difference.  
These findings suggest that LSP1 knockdown cells are less infectious 
due to inhibition between the egress and maturation stages of HIV replication. 
Interestingly, LSP1-KD cells showed lower levels of total HIV infection despite 
enhanced cell viability, meaning that less infection occurred despite there being 
more available cells to infect. Additionally, LSP1-KD reduces the infectiousness 
of HIV-1 virion produced. Therefore, understanding the physiology of LSP1 
during HIV-1 pathogenesis could provide novel therapeutic strategies to protect 
against HIV-1 and enhance T-cell viability. 
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Introduction 
The importance of finding an effective treatment for HIV/AIDS is without 
question as one of the world’s foremost public health crises. The disease known 
as Acquired Immunodeficiency Syndrome (AIDS) was first recognized as a 
clinical entity in 1981. By 1986, an international commission officially named the 
virus that causes AIDS the Human Immunodeficiency Virus (HIV).1,2 Since the 
first cases were reported in 1981, more than 25 million people worldwide have 
died from HIV/AIDS (hereafter referred to collectively as HIV). Currently, there are 
33.4 million people living with HIV.3 HIV is transmitted through the exchange of 
blood, seminal fluid, vaginal fluid, and breast milk. However, sexual transmission 
is the primary route, accounting for 75-90% of new infections.4 Each year, 
approximately 2 million people die from HIV, while another 2.7 million are newly 
infected with it. However, while HIV continues to be a global problem, it 
disproportionally affects more impoverished nations, especially those in Sub-
Saharan Africa, where 22.5 million are living with HIV.3 
Yet, even in wealthy countries like the United States, treatment for the 1.1 
million individuals living with HIV treatment carries a substantial economic 
burden, at an estimated lifetime cost of $380,000 per person ($618,900 for 
adults who initiate ART with CD4 cell count < 350/mL).3,5,6 Prevention has helped 
to reduce HIV prevalence rates in a small but growing number of countries and 
the number of new HIV infections are believed to be on the decline.3,5 However, 
the complexity of HIV leaves great uncertainty in where the next generation of 
7	  
HIV treatments shall arise. While genetic approaches appear promising, the 
technical hurdles to be overcome are staggering.7,8,9 
HIV-1 Structure & Function*,10 
Life expectancy for individuals living with HIV has improved by an 
impressive margin (<7 years in 1993, ~10 years in the late 90’s, and ~24 years at 
present).6 But HIV remains astonishing in how this relatively simple virus has 
remained incurable for decades despite the emergence of effective drug 
therapies9. The HIV-1 genome codes for fifteen different proteins, using its two 
identical positive sense (but not mRNA-like) genomic RNA strands (figure 1). Of 
the nine open reading frames in the genomic RNA, the portions that cause HIV 
to be classified as a retrovirus are the gag, pol, and env coding regions.  
*As this section is not the primary focus of the paper (and for my sanity), unless otherwise noted, references in 
the HIV-1 Structure & Function section will refer to the review article by Frankel and Young, or be in addition to it. 
 
          Image from Frankel & Young, 1998.10 
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The gag region codes for the (4) core structural proteins of the virus: MA 
(matrix, p17), CA (capsid, p24), NC (nucleocapsid, p7), and p6. MA, the N-
terminal region of the Gag polyprotein, is important for targeting Gag and Gag-
Pol precursor polyproteins to the plasma membrane prior to viral assembly. 
Furthermore, the MA protein lines the inner surface of the viral membrane, which 
appears to help incorporate Env glycoproteins into the virion, as well as facilitate 
infection of non-dividing cell types—mainly macrophages. The CA protein forms 
the core of the virus particle. Its C-terminal domain functions primarily in 
assembly, while its N-terminal domain is important for infectivity, through its 
association with the cellular chaperone cyclophilin A during viral uncoating. The 
NC protein coats genomic viral RNA and targets it for packaging in the 
assembling virion; it has also been implicated in other chaperone-like functions 
through the activity of its two zinc-finger domains, such as melting secondary 
RNA structures, participating in DNA strand exchange reactions during reverse 
transcription, and stimulating the integration step. Lastly, p6 is important for 
incorporating the accessory protein Vpr into the virus during assembly, as well 
as mediating efficient particle release. 
The pol region encodes for three proteins, PR (protease, p11), RT (reverse 
transcriptase), and IN (integrase, p32), which provide essential enzymatic 
functions. The viral protease is responsible for the final maturation of the 
otherwise non-infectious viral particles during the assembly and budding stages 
by cleaving Gag and Gag-Pol polyproteins, allowing the virus to undergo 
conformational changes. The PR protein (whose protease activity requires 
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dimerization) is cleaved off from the Gag-Pol polyprotein based on the 
polyprotein’s autocatalytic activity. The viral protease is also responsible for 
producing the final MA, CA, NC, p6, RT, and IN proteins, making it a prime 
target for drug design. As a retrovirus, HIV’s genomic RNA must first be 
transcribed into DNA before integration into the host chromosome. The RT 
enzyme (active as a heterodimer, p66 + p51) is capable of catalyzing both RNA-
dependent DNA polymerization (RDDP), also known as reverse transcription, 
and DNA-dependent DNA polymerization (DDDP), which completes the cDNA 
strand. Both strands of genomic RNA are needed for this HIV-1 replication, as 
they form a dimer that acts as the substrate for RT and stabilizes other 
replication intermediates.11 The RT enzyme also contains an RNase H domain, 
which functions to cleave the RNA portion of RNA-DNA hybrids, and also plays 
a role in creating a maker (a primer on the PPT that is unable to by hydrolyzed 
by RNase H) that specifies the beginning of the U3 long terminal repeat (LTR). 
Following reverse transcription, the integrase enzyme catalyzes a reaction that 
first leaves a 3’-OH CA-dinucleotide overhang on the viral DNA, which later 
becomes covalently bonded to the 5’ ends of the target DNA. The integrase 
uses negative sense viral DNA as the integration substrate and the host 
machinery subsequently completes the duplex. 
The env region codes for the surface (SU, gp120) glycoprotein as well as 
the viral transmembrane protein (TM, gp41), which dictate the binding, fusion, 
and tropism characteristics of HIV. The surface glycoprotein acts as a ligand to 
host CD4 protein, and binds to it, making it the major receptor of HIV-1. 
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However, HIV must also bind a coreceptor in order to initiate entry. It is thought 
that the V3 loop of SU (which is exposed upon CD4 binding) determines the viral 
coreceptor tropism—either CCR5 or CXCR4, although it is likely not the sole 
determinant given the variability of V3 sequences. Upon binding to CD4, Env 
(gp160) undergoes structural changes that allow SU to bind to the viral 
coreceptor and initiate the entry step. Following receptor/coreceptor binding, 
TM undergoes structural changes and mediates fusion between the viral and 
cellular membranes. 
Beyond its retroviral components, HIV-1 codes for two gene regulatory 
proteins, Tat and Rev, as well as four accessory proteins, Nef, Vif, Vpr, and Vpu. 
Tat is essential for viral replication because it increases both the rate of 
transcriptional initiation and the processivity of the host RNA polymerase II in 
producing viral proteins. However, unlike most transactivators, instead of 
binding to DNA, Tat binds to a hairpin structure, TAR, on the nascent viral 
mRNA, where it is thought to enhance phosphorylation of the C-terminal domain 
of RNA pol II through an interaction with the general transcription factor TFIIH. 
Similarly, Rev regulates replication by binding to RRE, a series of RNA hairpin 
structures that arise during transcription of the env region. Rev affects RNA 
splicing, stability, and contains a nuclear export signal. Rev regulates replication 
by creating a negative feedback loop that controls nuclear export of unspliced 
and singly spliced vs. multiply spliced viral mRNA into the cytoplasm. This 
feedback occurs because most early stage viral mRNAs are multiply spliced and 
encode the Tat, Rev, and Nef proteins. However, RRE must bind multiple Rev 
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monomers in order for unspliced and singly spliced viral mRNA to be exported. 
In this manner, Rev will eventually cause protein production to shift from multiply 
spliced viral mRNAs to singly spliced or unspliced viral mRNAs, helping to 
optimize the use of host cellular resources during replication. 
The accessory proteins are not necessary for HIV replication, but greatly 
increase replication efficiency and infectiousness of HIV in vivo. For example, 
Nef helps HIV infected cells escape CTLs through downregulation of MHC I 
molecules, and escape immune surveillance (e.g. by dendritic cells) through 
downregulation of CD4 by targeting it to lysosomes. Vif promotes the 
production of highly infectious mature virions. Its absence is especially 
noticeable in nonpermissive or semipermissive cell types, where it is thought to 
mimic a missing host factor utilized during replication. Vif enhances infection by 
stabilizing DNA replication intermediates and (via an unknown role) functioning 
in viral assembly and/or maturation. After uncoating, Vpr comes into play by 
transporting nucleoprotein complexes to nuclear pores (rather than to the 
interior of the nucleus), where it is theorized to form an ion channel. Additionally, 
Vpr can induce G2 cell cycle arrest prior to nuclear envelope breakdown and 
chromosome condensation, thereby increasing infection efficiency in both 
dividing and nondividing cells. Lastly, the Vpu protein aids in replication at three 
points. Vpu disentangles Env-CD4 complexes that form in the ER by degrading 
CD4; Vpu can downregulate MHC I surface expression; and Vpu can stimulate 
virion release by degrading tetherin, a cellular antiviral protein that inhibits the 
release of viral particles.12,24 
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Host Immunity 
Viruses enter cells by binding to specific proteins expressed on their 
surface. In the case of HIV-1, the CD4 antigen is the main receptor for viral 
entry; it is present on the following immune cells: CD4+ T lymphocytes, 
monocytes, dendritic cells, and brain microglia. Additionally, in cells lacking CD4 
receptors, such as fibroblasts, an Fc receptor site or complement receptor site 
may be used instead for entry of HIV; gp120-independent infection has also 
been reported.13,14 The CD4 protein interacts with MHC class II receptors used 
by immune cells for antigen presentation—a process whereby other immune 
cells display the degraded fragments of proteins from invading pathogens to T 
cells. The T cells recognize these antigens via specialized antigen receptors—T 
Cell Receptors (TCRs)—which share structural similarities to antibodies, 
however TCRs can only recognize a pathogen’s protein fragments when bound 
to MHC molecules. Upon antigen recognition, CD4+ T cells can then activate 
other immune cells (including B cells and CD8+ T Cells) to respond to the 
infection.15,16 
In addition to the CD4 receptor, HIV-1 must utilize a co-receptor to 
facilitate entry into the cell; the co-receptor used determines viral tropism. Most 
primary HIV-1 isolates (new cases of HIV-1 transmission) utilize the CCR5 
chemokine receptor (R5 viruses). The other major HIV-1 variant utilizes the 
CXCR4 chemokine receptor (X4 viruses) as its co-receptor. However, CD4+ T 
lymphocytes display an unequal distribution between CCR5+ and CXCR4+ cell 
subtypes; 79% of CD4+ T lymphocytes are exclusively CXCR4+, whereas 4% of 
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CD4+ T lymphocytes are exclusively CCR5+. Approximately 6% are double 
positive, and the remaining 11% of CD4+ T cells express neither CCR5 nor 
CXCR4 at detectable levels on the cell surface. 17 
During the later stages of viral infection, the viral phenotype shifts from 
R5 to X4 in approximately 50% of individuals.18 The clinical significance of this 
switch is that the HIV-1 in circulation has effectively increased its pool of 
susceptible CD4+ T cells from 10% to 89%.17 Additionally, CXCR4 is present on 
several other cell types, including naïve T cells, B cells, and monocytes, which 
some data have implicated in creating a bystander effect during HIV-1 
infection.19 The increased pool of susceptible cells results in a shift towards 
rapid T cell infection and depletion, leading to the immune dysfunction 
characteristic of AIDS patients (figure 2).20  
Figure 2:16 Timeline of HIV-AIDS Progression 
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The immune system is unsuccessful in clearing HIV due to three primary 
viral evasion strategies, namely, latency, mutation/antigenic drift, and subversion 
of the host immune system. Latency dictates that patients cannot discontinue 
an effective drug therapy without resurgence of the virus. The mutability of the 
virus dictates that the emergence of drug resistance is inevitable and that viral 
load suppression by the host immune system will fade as new HIV quasispecies 
appear. Meanwhile, HIV interacts with the immune system in such a manner that 
its activation is an intended outcome in HIV pathogenesis. Given these 
strategies, it is clear that a multi-pronged and systematic approach to halting 
HIV pathogenesis is required.21 
 
HIV-1 Pathogenesis & LSP1 
Since sexual transmission accounts for 75-90% of new HIV infections, 
HIV-1 transmission through mucosal surfaces has become a growing focal point 
in the field of HIV research.4 Dendritic cells are considered one of the early 
targets of HIV-1 infection and are key players in the wider dissemination of HIV. 
In what is known as the DC-SIGN pathway, HIV binds to the SIGN molecule with 
high affinity. However, this binding does not trigger the fusogenic activity 
needed for productive HIV infection to occur in DCs. Instead, the still-infectious 
HIV virion can remain bound on the cell’s outer surface for many days. Dendritic 
cells, as antigen presenting cells, inevitably encounter other immune cells. Thus, 
as the DC forms an immunological synapse with a nearby immune cell, HIV may 
then bind the necessary receptors to infect the contacted cell.22 
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However, it was discovered that Leukocyte Specific Protein 1 (LSP1, also 
known as Lymphocyte Specific Protein 1, WP34, Leufactin, 47 KDa Actin 
Binding Protein, or pp52) interacts with DC-SIGN to mediate transfer of 
internalized HIV-1-SIGN complexes to the proteasome.23 This finding was further 
explored and demonstrated that the absence or downregulation of LSP1, as 
would be expected, caused enhanced trans (cell-to-cell) HIV-1 transmission to T 
cells.25 The LSP1 gene encodes for an intracellular filament-actin binding 
protein, known to bind the ends of actin filaments of the cell membrane together 
in bundles.26 Through this activity, LSP1 is able to affect actin 
polymerization/cytoskeletal remodeling, cellular motility, chemotaxis, and 
aspects of molecular trafficking.26,27 Furthermore, LSP1 has a calcium binding 
domain and is a major downstream substrate of p38 mitogen-activated protein 
kinase and PKC.28,29 However, while LSP1 is also expressed in neutrophils, 
macrophages, activated PBMCs, and endothelial cells, its function in 
lymphocytes is unknown.28,30 Since >95% of circulating HIV-1 is produced by 
newly infected CD4+ T cells, elucidating the role of LSP1 during HIV-1 infection 
of T cells is key to better understanding HIV-1 pathogenesis. 
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Materials and Methods 
A reverse genetics strategy was employed to study the role of LSP1 
during HIV-1 infection in T-cells. To do so, an shRNA plasmid construct was 
constructed to transcriptionally silence the LSP1 gene. An X4 tropic (T tropic) 
HIV-1 virus was chosen because of its ability to infect naïve T cells.32 
 
Cell Culture 
 The cell line MT4 was used for this study. MT4 cells were originally 
derived from an adult with T cell leukemia (HTLV-1 transformed; though rare, 
low level, transient HTLV shedding is known to occur).31 X4 HIV-1 strains tend to 
cause (compared to R5 isolates) syncytium formation and cell death.32 X4 HIV-1 
pathogenesis is especially robust in MT4 cells since in the LTR of HIV-1, the 
enhancer region of U3 can also bind regulatory proteins of heterologous viruses, 
in particular, HTLV-1 Tax protein.49 Once established, the LSP1 knockdown (KD) 
and non-targeting shRNA (NT) cell lines were cultured in RPMI 1640 medium 
supplemented with (v/v) 10 % FBS and 1 % Penicillin-Streptomycin (cRPMI). 
Cells were maintained by removing old media / excess cell growth and replacing 
the volume with fresh cRPMI (approximately every 2-4 days depending on 
desired growth and media pH indicator), and incubated at 37 ˚C and 5 % CO2 in 
a humidified environment. 
Two different (antisense) binding sites on the LSP1 mRNA transcript were 
(separately) targeted to knockdown LSP1 gene transcripts. This was done using 
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a stably transfected (Lipofectamine method) shRNA plasmid in MT4 cells; the 
respective cell lines were dubbed LSP1-09-KD and LSP1-10-KD (“09” and 
“10”); non-targeting shRNA was used as a control. Following transfection, the 
09, 10, and NT constructs were cultured from single cell clones (SCCs). SCCs 
were established using serial dilutions in a 96 well plate and selected by GFP 
fluorescence expressed from the plasmid vehicle. Selected SCCs were then 
subjected to drug selection with Puromycin at a dose of 1 µg/mL (selection dose 
was optimized; data not shown) for 2 weeks.33 Drug selection was then 
discontinued as to not interfere with normal cellular gene or protein expression, 
since Puromycin is a (quite toxic) protein synthesis inhibitor that functions by 
causing premature chain release during translation. 
 
Verification of Knockdown Construct 
After RNA extraction with Trizol reagent and reverse transcription were 
performed (per manufacturer’s instructions), LSP1 gene expression was 
quantified by RT-PCR using SYBR® Green manufacturer’s protocols.34 Gene 
knockdown was periodically monitored throughout the duration of the study 
(data not shown). Following protein estimation, sample loading was 
standardized to 50 ng of protein and analyzed by western blot, as described 
previously.35 Since the GAPDH gene is often stably and constitutively expressed 
at high levels in most tissues and cells, and is considered a “housekeeping 
gene,” it was used as a loading control for the western blot.50  
 Cell Proliferation Assay 
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Since LSP1, through its calcium binding domain, may act in a negative 
feedback loop in cell cycle control,29 a CFSE proliferation assay was performed 
to characterize the cell lines over a 3 day period. CFSE is a non-toxic dye. As 
labeled parental cells divide, the CFSE fluorescence is partitioned between the 
daughter cells. Therefore, cell proliferation can be tracked by measuring mean 
CFSE intensity per cell over time.36 
 
Quantification of HIV Production 
Effects of LSP1-Knockdown during HIV-1 infection were examined in NT 
vs. KD cell lines using the X4 tropic HIV-1 strain, HIVIIIB. A quantity of 106 cells 
were incubated with 10 ng p24 of HIVIIIB  (~107 virion per ng of p24; approximate 
MOI of 10) for 1 hr at 37 ˚C, and then washed to remove unbound HIV. The 
supernatant of infected cells was collected days 1-4 post-infection, and the total 
virion content was quantified by p24 (HIV capsid) ELISA assay. 
 
Examination of HIV Infectivity 
After normalizing p24 concentrations from the supernatant of the NT vs. 
KD cells, the infectiousness of the HIV-1 virion produced was verified by an 
LTR-driven GHOST reporter cell line, which was quantified by flow cytometry 
using CellQuest software (BD Biosciences). In this assay, the amount of 
infectious HIV is measured by proxy of GFP fluorescence, where GFP+ cells 
indicate HIV infection since GFP is expressed under the control of the viral 
LTR.37 Please note: This is not a co-culture experiment; cells expressing GFP 
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from the plasmid vehicle are not intermixed with the GHOST cell reporter line. 
 
Determination of Replication Interference 
In order to determine where LSP1 knockdown may be interfering with 
viral replication, a viral binding and entry assay was performed as described 
previously,35 but are described below briefly. These assays were chosen since 
the effect of LSP1 knockdown on HIV-1 infection seemed to have been 
mediated through altered cytoskeletal dynamics given the experimental results 
which showed discrepancies in both total HIV-1 virion produced and the 
proportion of infectious HIV-1 virion produced. 
For the virus binding assay, cells were infected with HIV-1NL4-3 (X4 tropic) 
at a concentration of 40 ng p24/106 cells. After 1 hr incubation at 4 ˚C, the cells 
were extensively washed with ice-cold PBS to remove unbound viruses, 
transferred to fresh tubes, and finally lysed in ice-cold lysis buffer (1% Triton X-
100). Total cell protein was estimated, and all samples were normalized for 
protein content. Virus binding was monitored by measuring the amount of p24 in 
the cell lysates by ELISA.  
For the virus entry assay, cells were incubated with HIV-1NL4-3 for 3 hr at 
37 ˚C. Following incubation, the cells were washed five times with PBS, treated 
with trypsin for 5 min at 37 ˚C to remove the uninternalized virus from the 
surface, and washed once with cRPMI and five times with PBS. Lysis and p24 
ELISA were performed in the same manner as during the binding assay.   
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Results 
Before further study could be conducted, the effectiveness of the plasmid 
construct had to be verified. Western blot analysis confirmed that LSP1 
knockdown with the shRNA plasmid construct was effective at reducing LSP1 
protein expression (figure 3), without affecting normal gene expression (GAPDH 
was used as a representative measure). 
 
Figure 3: Western Blot in transfected MT4 Cells 
 
Cell Proliferation Assay 
Thereafter, the cells were characterized for proliferation (figure 4), since 
as mentioned earlier, HIV-1 accessory protein Vpr induces growth cycle arrest in 
order to enhance replication efficiency, making cell cycle characteristics an area 
of interest. 
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Figure 4: Viability of Transfected MT4 cells 
 
The proliferation assay revealed that LSP1-KD results in enhanced 
viability, with both the 10-shRNA and 09-shRNA variants displaying an increase 
in proliferation (fig. 4). This data also gives credence to a previous hypothesis 
that knockdown of LSP1 would accelerate the cellular growth cycle by 
eliminating LSP1 from a negative feedback loop involving calcium regulation.29 
Additionally, based on a qualitative assessment of the western blot results, 
LSP1 knockdown appears to accelerate the growth cycle / cell proliferation in a 
dose dependent manner since the relative proliferation, 10 > 09 > NT, is 
concordant with the relative protein expression shown in the western blot. As 
such, a future area of study would be to examine the cell cycles of LSP1-KD vs. 
NT cells during infection with WT HIV-1 or an HIV-1 Vpr-mutant.
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 Quantification of HIV Production 
The ability of the LSP1-KD cell line was then assessed for its ability to 
support productive HIV-1 infection. The total amount of virion produced was 
measured by p24 ELISA (figure 5). 
 
Figure 5: Synchronized HIV-1 Infection of MT4 cells 
 
The data (fig. 5) indicates a substantial and sustained drop in newly 
produced HIV-1 p24 levels, with 40%, 60%, and 80% reductions in relative 
virion production over days 1-3. The increase in relative p24 levels at day 4 may 
at first seem to indicate decay in the knockdown’s protective effect. However, a 
cursory examination under a microscope revealed that this effect was likely due 
to the cytopathic effects of HIV-1 infection. That is—nearly all the NT cells had 
died and therefore generated no additional virion. Meanwhile, since viruses 
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replicate in bursts, and HIV-1 on average requires 52 hr between the export of 
one generation of virions and the next, the increase in relative p24 levels on day 
4 in LSP1-KD cells is most likely the 2nd replication burst.38,39 
 
Determination of Replication Interference 
Since the earlier quantification of relative total p24 levels indicated that 
HIV replication is being inhibited when LSP1 is knocked down, it is important to 
determine where in the viral life cycle this is occurring as to narrow down what 
interaction is mediating the inhibition of replication. Binding and entry were 
analyzed as being among the more likely interference points (figure 6). 
 
Figure 6: Examination of HIV-1 Binding and Entry with LSP1-KD in MT4 cells 
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The binding assay (fig. 6) showed a significant reduction (p = 0.02) in HIV-
1 binding in LSP1-KD cells—62%, while the entry assay showed no significant 
differences. The significance and implications of these results will be explored in 
the discussion section. 
 
Examination of HIV Infectivity 
However, a measurement of total virion produced alone may not illustrate 
the full protective effect of LSP1 knockdown against HIV-1 infection. In 
retroviruses such as HIV, the ratio of noninfectious to infectious physical 
particles typically ranges from 105:1 to 107:1.39 As such, it was prudent to 
examine if the HIV-1 particles that were produced during infection of LSP1-KD 
cells were as infectious as those of the control sample. Therefore, the relative 
amount of infectious virion produced was compared (figure 7) using a reporter 
cell line, GHOST cells, wherein GFP is expressed under the control of an LTR, 
which is activated upon infection with a retrovirus. 
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Figure 7: Infection of GHOST cells using infected LSP1-KD and NT Supernatant 
 
 
The data (fig. 7) indicates that LSP1-KD cells produce a smaller 
proportion of infectious HIV-1 virion (vs. total HIV-1 virion) compared to NT 
controls. Stated otherwise, the relative infectiousness of HIV-1 in the 
supernatant from infection of LSP1-KD cells vs. NT cells was reduced by 44% 
with LSP1 knockdown. 
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Discussion 
HIV-1 infections have proved extremely difficult to overcome through 
conventional interventions because of the mutability and evasiveness of the 
virus. As such, a growing body of evidence supports a case for the notion that 
therapies directed towards human endogenous targets rather than viral targets 
may be a more successful way to control HIV-1 infections.7,8,9 Previous studies 
of LSP1 made a convincing argument that LSP1 knockdown would enhance 
HIV-1 spread through cell-to-cell transmission (from DCs to T cells) because 
LSP1 binds to the cytoplasmic region of DC-SIGN (independently of LSP1’s F-
actin binding domain) and helps to direct DC-SIGN bound to HIV-1 to the 
proteasome.23 However, the above data taken in context with previous work 
form the Ganju lab and others48 seems to indicate that a more nuanced effect 
would arise in vivo. 
Previously,28 we have shown that stimulation with gp120 induced iDC 
chemotaxis via a downstream signaling pathway (figure 8) that activates LSP1. 
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Figure 8: Proposed Signaling Pathway for gp120-induced chemotaxis of iDCs                       
         
Image from Ganju, et al., 2009.28 
 
In that study, an siRNA knockdown of LSP1 was utilized, which is a less 
efficient (only ~75% downregulation) and more transient knockdown than the 
shRNA construct used in this study, resulted in a 53% attenuation in gp120 
induced iDC chemotaxis because LSP1’s association with F-actin is need to 
induce chemotaxis. A stronger LSP1 knockdown would likely amplify this 
attenuation. Thus, by inhibiting gp120 induced APC migration, viral spread 
might be lessened. 
However, to conclude that the importance of LSP1 is limited to its 
association with F-actin (which seems to be the extent of most publication’s 
background information on it) would neglect some of the earliest findings about 
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LSP1. Three distinct subcellular pools of LSP1 protein are known to exist—
cytoplasmic, cytoskeletal, and plasma membrane associated pools.40 This 
implicates distinct functional significance and differing post-translational 
modifications. The cytoplasmic LSP1 (which also translocates to the 
cytoskeletal pool upon phosphorylation by PKC) likely functions as an 
intermediate effector molecule by responding to the transient Ca2+ influxes that 
occur when membrane receptor cross-linking occurs.40 The LSP1 Ca2+ binding 
domain is evolutionarily conserved across species, which strongly suggests a 
continuing functional importance.40 The cytoskeletally associated LSP1 is known 
to be phosphorylated by casein kinase II, protein kinase C and MAPKAPK2.41 
The plasma membrane associated LSP1 is N-glycosylated and capable of 
interacting with immunoglobin-like domains.42 Several isoforms of LSP1 exist,30 
so the N-glycosylated variant is all but certainly the result of a yet to be 
indentified alternative splicing combination. 
Confocal microscopy data from previous studies in our lab support 
findings observed in early LSP1 studies regarding B cell activation about its 
participation in a capping/polarization effect when an Ig-like receptor binds a 
ligand. The authors theorized that LSP1 capping was occurring either due to 
Ca2+ related signaling events causing cytoplasmic LSP1 translocation, or, due to 
LSP1 association with the cytoskeleton.40 While a non-specific effect from Ca2+ 
related signaling events is difficult to rule out,46,47 our imaging data28 (figure 9, 
left) supports the LSP1-cytoskeleton “capping” hypothesis through an effect on 
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actin. This is further confirmed through the use of a drug inhibitor of LSP1 
phosphorylation by p38 (figure 9, right). 
 
Figure 9: Confocal Microscopy of gp120-incuced Cytoskeleton Rearrangements 
  
Image from Ganju, et al., 2009.28 
 
With this data in mind, now consider the results of the HIV-1 binding and 
entry assay in the LSP1-KD vs. NT cells. HIV-1 binding was significantly 
inhibited in LSP1-KD cells compared to NT, while virtually no difference in the 
amount of internalized p24 was observed in the entry assay. It remains unclear 
why HIV-1 binding was inhibited in LSP1-KD cells, however, detailed studies on 
the HIV-1 binding step strongly contradict explanations involving Ca2+, binding 
kinetics, receptor signaling, and the presence or absence of other GPCR-related 
signaling proteins.43,44,45 The only explanation that is consistent with this data is 
that LSP1-KD (through an unknown mechanism) reduces the binding affinity of 
CD4 to gp120. It is consistent because it has been shown that high affinity CD4-
gp120 binding is not necessary for HIV-1 entry because the binding step is fully 
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reversible.43 Meanwhile, the fusion step is rapid enough that making initial 
contact with the co-receptor is essentially irreversible.44 As such, the 
experimenters noted that relatively normal levels of HIV-1 entry had been 
observed even in instances where no binding was detected by the assay.44 
Therefore, given the remaining data (the decrease in the relative total HIV-
1 virion produced and the decrease in the relative proportion of infectious HIV-1 
virion produced), a reasonable inference can be made about where in the 
replication cycle the LSP1 knockdown is creating interference. The reduced 
proportion of infectious virion points toward an effect at the maturation stage 
(post-egress). Alternatively, this could be occurring due to an interaction with 
LSP1 and the Nef accessory protein, which is probable based on previous data 
from our lab which showed a close co-localization of Nef and F-actin (figure 
10).35  Since Nef is packaged in the virion and increases the infectiousness of 
the virus, it is feasible that the reduced infectiousness of the LSP1-KD cells is 
mediated through interference with Nef packaging.  
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Figure 10: Co-Localization of Virus & Host Factors during HIV-1 Infection 
 
Image from Ganju, et al., 2012.35 
 
In contrast, the reduced total HIV-1 virion content could point to an effect 
during the budding/egress stage, in which case the HIV-1 virion would be 
retained intracellularly, similar what occurs when tetherin protein expression is 
upregulated.12 
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Conclusion 
Given the multitude of possible functional interactions LSP1 is capable of 
participating in, this study was neither meant to resolve—nor capable of 
resolving—the nature of the interaction that is occurring with LSP1 during HIV-1 
infection. It is, however, able to provide clues, as well as tantalizing data about 
the functional outcomes that might be achieved from further study. 
Overall, this study does yield the interesting finding that LSP1-KD cells 
showed lower levels of HIV infection despite enhanced cell viability, meaning 
that less infection occurred despite there being more available cells to infect. 
Additionally, it demonstrated that LSP1-KD reduces total HIV-1 replication as 
well as decrease the infectiousness of the HIV-1 virion produced. Since 
permissive HIV-1 infection in CD4+ T cells is the primary contributor to viral load 
in HIV+ persons, therapeutic strategies that target LSP1 could prove promising 
for patients whose viremia is not well controlled or patients who present with 
severe CD4+ T cell depletion. Therefore, understanding the physiology of LSP1 
during HIV-1 pathogenesis could provide novel therapeutic strategies to protect 
against HIV-1 and enhance T-cell viability. 
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 HIV-1 Replication Cycle, beginning from the Provirus stage (Step 1). 
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